Disc Medicine, Inc.

Fortress Value Acquisition Corp. IV, trading under the ticker FSDC and sponsored by Fortress Investment Group, is a blank-check company that completed its business combination with Disc Medicine, Inc., a clinical-stage biopharmaceutical company focused on hematologic diseases. The SPAC conducted its IPO in 2021, targeting the healthcare and life sciences sector. An 8-K was filed on June 14, 2024, under accession number 0001193125-24-161603, disclosing a material corporate event tied to the combined entity. Disc Medicine concentrates its pipeline on treatments for serious blood disorders, positioning the post-merger company within the rare disease segment of biopharma. Sign up at SpacDesk for complete filing history, timeline data, and deal analytics on FSDC and hundreds of other SPACs.